Featured Research
from universities, journals, and other organizations
Scientists announce anti-HIV agent so powerful it can work in a vaccine
Date:
February 18, 2015
Source:
The Scripps Research Institute
Summary:
In a remarkable new advance against the virus that causes AIDS, scientists have announced the creation of a novel drug candidate that is so potent and universally effective, it might work as part of an unconventional vaccine.
Scanning electron micrograph of HIV particles infecting a human T cell.
Credit: NIH
In a remarkable new advance against the virus that causes AIDS, scientists from the Jupiter, Florida campus of The Scripps Research Institute (TSRI) have announced the creation of a novel drug candidate that is so potent and universally effective, it might work as part of an unconventional vaccine.
Related Articles
The research, which involved scientists from more than a dozen research institutions, was published February 18 online ahead of print by the journal Nature.
The study shows that the new drug candidate blocks every strain of HIV-1, HIV-2 and SIV (simian immunodeficiency virus) that has been isolated from humans or rhesus macaques, including the hardest-to-stop variants. It also protects against much-higher doses of virus than occur in most human transmission and does so for at least eight months after injection.
"Our compound is the broadest and most potent entry inhibitor described so far," said Michael Farzan, a TSRI professor who led the effort. "Unlike antibodies, which fail to neutralize a large fraction of HIV-1 strains, our protein has been effective against all strains tested, raising the possibility it could offer an effective HIV vaccine alternative."
Blocking a Second Site
When HIV infects a cell, it targets the CD4 lymphocyte, an integral part of the body's immune system. HIV fuses with the cell and inserts its own genetic material -- in this case, single-stranded RNA -- and transforms the host cell into a HIV manufacturing site.
The new study builds on previous discoveries by the Farzan laboratory, which show that a co-receptor called CCR5 contains unusual modifications in its critical HIV-binding region, and that proteins based on this region can be used to prevent infection.
With this knowledge, Farzan and his team developed the new drug candidate so that it binds to two sites on the surface of the virus simultaneously, preventing entry of HIV into the host cell.
"When antibodies try to mimic the receptor, they touch a lot of other parts of the viral envelope that HIV can change with ease," said TSRI Research Associate Matthew Gardner, the first author of the study with Lisa M. Kattenhorn of Harvard Medical School. "We've developed a direct mimic of the receptors without providing many avenues that the virus can use to escape, so we catch every virus thus far."
The team also leveraged preexisting technology in designing a delivery vehicle -- an engineered adeno-associated virus, a small, relatively innocuous virus that causes no disease. Once injected into muscle tissue, like HIV itself, the vehicle turns those cells into "factories" that could produce enough of the new protective protein to last for years, perhaps decades, Farzan said.
Data from the new study showed the drug candidate binds to the envelope of HIV-1 more potently than the best broadly neutralizing antibodies against the virus. Also, when macaque models were inoculated with the drug candidate, they were protected from multiple challenges by SIV.
"This is the culmination of more than a decade's worth of work on the biochemistry of how HIV enters cells," Farzan said. "When we did our original work on CCR5, people thought it was interesting, but no one saw the therapeutic potential. That potential is starting to be realized."
In addition to Farzan, Gardner and Kattenhorn, authors of the study, "AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges," include Hema R. Kondur, Tatyana Dorfman, Charles C. Bailey, Christoph H. Fellinger, Vinita R. Josh, Brian D. Quinlan, Pascal Poignard and Dennis R. Burton of TSRI; Jessica J. Chiang, Michael D. Alpert, Annie Y. Yao and Ronald C. Desrosiers of Harvard Medical School; Kevin G. Haworth and Paula M. Cannon of the University of Southern California; Julie M. Decker and Beatrice H. Hahn of the University of Pennsylvania; Sebastian P. Fuchs and Jose M. Martinez-Navio of the University of Miami Miller School of Medicine; Hugo Mouquet and Michel C. Nussenzweig of The Rockefeller University; Jason Gorman, Baoshan Zhang and Peter D. Kwong of the National Institutes of Health; Michael Piatak Jr. and Jeffrey D. Lifson of the Frederick National Laboratory for Cancer Research; Guangping Gao of the University of Massachusetts Medical School; David T. Evans of the University of Wisconsin; and Michael S. Seaman of Beth Israel Deaconess Medical Center.
The work was supported by the National Institutes of Health (grants R01 AI091476, R01 AI080324, P01 AI100263, RR000168 and R01AI058715).
Story Source:
The above story is based on materials provided by The Scripps Research Institute.Note: Materials may be edited for content and length.
Journal Reference:
- Matthew R. Gardner, Lisa M. Kattenhorn, Hema R. Kondur, Markus von Schaewen, Tatyana Dorfman, Jessica J. Chiang, Kevin G. Haworth, Julie M. Decker, Michael D. Alpert, Charles C. Bailey, Ernest S. Neale, Christoph H. Fellinger, Vinita R. Joshi, Sebastian P. Fuchs, Jose M. Martinez-Navio, Brian D. Quinlan, Annie Y. Yao, Hugo Mouquet, Jason Gorman, Baoshan Zhang, Pascal Poignard, Michel C. Nussenzweig, Dennis R. Burton, Peter D. Kwong, Michael Piatak, Jeffrey D. Lifson, Guangping Gao, Ronald C. Desrosiers, David T. Evans, Beatrice H. Hahn, Alexander Ploss, Paula M. Cannon, Michael S. Seaman, Michael Farzan. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature, 2015; DOI: 10.1038/nature14264
Cite This Page:
Share This
More From ScienceDaily
More Health & Medicine News
Wednesday, February 18, 2015
Featured Research
from universities, journals, and other organizations
New Weapon in the Fight Against Cancer Could Be in Your Body Already
Feb. 18, 2015 — A tool for keeping the most common forms of cancer at bay could be in your gut, a new study concludes. For the study, the research team tested thousands of chemicals found in the body with the help... full story
- New Weapon to Fight Cancer in Your Gut?
- Nanotechnology: Measurements of Molecule Circuits
- Nanodrones for Atherosclerosis
- Personalized Cellular Therapy for Brain Cancer
- Teen Brain Scans Reveal a Key to Weight Loss
- Autism Genes Activate During Brain Development
- Epigenomics of Alzheimer's Disease Progression
- Using MRI to Visualize Pancreas Inflammation
- Chromosome 'Repair' Gene Predicts Outcomes
- Type 2 Diabetes? You Should Exercise After Dinner
newer top stories | older top stories
Breaking News:
Related Stories
Study of Antibody Evolution Charts Course Toward HIV Vaccine
Mar. 2, 2014 — In an advance for HIV vaccine research, a scientific team has discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting a site on the virus called... full story
Strange & Offbeat Stories
Health & Medicine
- Women Seek Greater Variety in Men and Consumer Products Near Ovulation
- Mothers Can Pass Traits to Offspring Through Bacteria's DNA, Mouse Study Shows
- See Here Now: Telescopic Contact Lenses and Wink-Control Glasses
- Making Teeth Tough: Beavers Show Way to Improve Our Enamel
- First-in Human: Tumor Suctioned from Vein of Cancer Patient to Allow Minimally Invasive Kidney Surgery
Mind & Brain
- Women Seek Greater Variety in Men and Consumer Products Near Ovulation
- Even Animals Compose: What It Means to Be a Musical Species
- Complex Nerve-Cell Signaling Traced Back to Common Ancestor of Humans and Sea Anemones
- Curious Monkeys Share Our Thirst for Knowledge
- New Fluorescent Protein Permanently Marks Neurons That Fire
Living & Well
- Women Seek Greater Variety in Men and Consumer Products Near Ovulation
- Will Your Partner Stay or Stray? Look at Finger Length
- F-Bombs Notwithstanding, All Languages Skew Toward Happiness: Universal Human Bias for Positive Words
- Settling for 'Mr. Right Now' Better Than Waiting for 'Mr. Right', Shows Model of Digital Organisms
- Drug-Resistant Bacteria Lurk in Subway Stations, High School Students Discover
In Other News
... from NewsDaily.com
Science News
- U.S. must invest to keep ahead of China in space, hearing told
- Scientists unveil map of 'epigenome,' a second genetic code
- Marijuana munchies are all in the brain, U.S. study finds
- Strongest known natural material – spider silk or limpet teeth?
- In a first for a fish, Oregon chub removed from endangered list
Health News
- Even light activity may help the hearts of older people
- Ebola cases fall in West Africa, but challenges remain: WHO
- Activists seek to put porn actor condom requirement on California ballot
- Canadian cow with BSE born after feed precautions
- Toothpaste-mouth rinse combo washes out harmful bacteria
Environment News
- Istanbul snowstorm grounds planes, shuts Bosphorus to tankers
- EU introduces new rules to make cooking greener
- Dutch gas field earthquake dangers ignored for decades: Safety Board
- Brazil finally gets some rain, but rationing still looms
- Citigroup to set aside $100 billion to fund green initiatives
Technology News
- Google's YouTube to launch subscription model in "few months": CNBC
- T-Mobile presses U.S. to change rules for sale of airwaves
- Samsung to buy mobile payment service provider LoopPay
- U.S. marshals to auction 50,000 bitcoins from Silk Road
- InterDigital loses another round in patent fight
No comments:
Post a Comment
Please leave a comment-- or suggestions, particularly of topics and places you'd like to see covered